Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 103

1.

Upregulated microRNAs in membranous glomerulonephropathy are associated with significant downregulation of IL6 and MYC mRNAs.

Barbagallo C, Passanisi R, Mirabella F, Cirnigliaro M, Costanzo A, Lauretta G, Barbagallo D, Bianchi C, Pagni F, Castorina S, Granata A, Di Pietro C, Ragusa M, Malatino LS, Purrello M.

J Cell Physiol. 2019 Aug;234(8):12625-12636. doi: 10.1002/jcp.27851. Epub 2018 Dec 4.

PMID:
30515781
2.

Pulse wave velocity differs between ulcerative colitis and chronic kidney disease.

Zanoli L, Lentini P, Boutouyrie P, Fatuzzo P, Granata A, Corrao S, Gaudio A, Inserra G, Rapisarda F, Rastelli S, Laurent S, Malatino LS, Castellino P.

Eur J Intern Med. 2018 Jan;47:36-42. doi: 10.1016/j.ejim.2017.08.020. Epub 2017 Aug 19.

PMID:
28830726
3.

Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men.

Attinà TM, Drummond ID, Malatino LS, Maxwell SR, Webb DJ.

Am J Hypertens. 2013 Mar;26(3):342-50. doi: 10.1093/ajh/hps057. Epub 2013 Jan 7.

PMID:
23382484
4.

Hepatocyte growth factor and cardiomyopathy in dialysis patients.

Malatino LS, Cataliotti A, Stancanelli B, Zoccali C.

Hypertension. 2012 Sep;60(3):e24; author reply e25-6. doi: 10.1161/HYPERTENSIONAHA.112.198424. Epub 2012 Aug 6. No abstract available.

PMID:
22868387
5.

Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats.

Cataliotti A, Tonne JM, Bellavia D, Martin FL, Oehler EA, Harders GE, Campbell JM, Peng KW, Russell SJ, Malatino LS, Burnett JC Jr, Ikeda Y.

Circulation. 2011 Mar 29;123(12):1297-305. doi: 10.1161/CIRCULATIONAHA.110.981720. Epub 2011 Mar 14.

6.

Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients.

Testa A, Mallamaci F, Macrì R, Pisano A, Spoto B, Malatino LS, Stancanelli B, Tripepi G, Benedetto FA, Zoccali C.

J Hypertens. 2010 Aug;28(8):1745-51. doi: 10.1097/HJH.0b013e32833bd21b.

PMID:
20543711
7.

The prevalence of the cardiac origin of chest pain: the experience of a rural area of southeast Italy.

Cilia C, Malatino LS, Puccia G, Iurato MA, Noto G, Tripepi G, Rosen P, Stancanelli B.

Intern Emerg Med. 2010 Oct;5(5):427-32. doi: 10.1007/s11739-010-0401-x. Epub 2010 May 7.

PMID:
20449691
8.

Soluble e-selectin is an inverse and independent predictor of left ventricular wall thickness in end-stage renal disease patients.

Stancanelli B, Malatino LS, Cataliotti A, Bellanuova I, Mallamaci F, Tripepi G, Benedetto FA, Leonardis D, Fatuzzo P, Rapisarda F, Zoccali C.

Nephron Clin Pract. 2010;114(1):c74-80. doi: 10.1159/000252806. Epub 2009 Oct 23.

PMID:
19851079
9.

Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients.

Mallamaci F, Benedetto FA, Tripepi G, Cutrupi S, Pizzini P, Stancanelli B, Seminara G, Bonanno G, Rapisarda F, Fatuzzo P, Malatino LS, Zoccali C.

J Hypertens. 2008 Sep;26(9):1875-82. doi: 10.1097/HJH.0b013e328307c3d2.

PMID:
18698224
10.

Coronary heart disease extension as a predictor of atherosclerotic renal artery stenosis.

Stancanelli B, Maugeri E, Nicosia A, Ferrante F, Tripepi G, Zoccali C, Malatino LS.

J Nephrol. 2008 May-Jun;21(3):421-5.

PMID:
18587732
11.

Contribution of the M3 muscarinic receptors to the vasodilator response to acetylcholine in the human forearm vascular bed.

Attinà TM, Oliver JJ, Malatino LS, Webb DJ.

Br J Clin Pharmacol. 2008 Aug;66(2):300-3. doi: 10.1111/j.1365-2125.2008.03194.x. Epub 2008 Apr 10.

12.

Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients.

Attinà TM, Malatino LS, Maxwell SR, Padfield PL, Webb DJ.

J Hypertens. 2008 Mar;26(3):501-7. doi: 10.1097/HJH.0b013e3282f382ff.

PMID:
18300861
13.

Endogenous ouabain and cardiomyopathy in dialysis patients.

Stella P, Manunta P, Mallamaci F, Melandri M, Spotti D, Tripepi G, Hamlyn JM, Malatino LS, Bianchi G, Zoccali C.

J Intern Med. 2008 Mar;263(3):274-80. Epub 2007 Dec 7.

14.

Circulating E-selectin as a risk marker in patients with end-stage renal disease.

Malatino LS, Stancanelli B, Cataliotti A, Bellanuova I, Fatuzzo P, Rapisarda F, Leonardis D, Tripepi G, Mallamaci F, Zoccali C.

J Intern Med. 2007 Oct;262(4):479-87.

15.

Pulse pressure is an independent predictor of aortic stiffness in patients with mild to moderate chronic kidney disease.

Stancanelli B, Malatino LS, Malaponte G, Noto P, Giuffrè E, Caruso A, Gagliano C, Zoccolo AM, Puccia G, Castellino P.

Kidney Blood Press Res. 2007;30(5):283-8. Epub 2007 Jul 6.

16.

Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease.

Zoccali C, Benedetto F, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P, Malatino LS, Bonanno G, Seminara G.

J Hypertens. 2006 Oct;24(10):2039-46.

PMID:
16957565
17.

Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy.

Belluardo P, Cataliotti A, Bonaiuto L, Giuffrè E, Maugeri E, Noto P, Orlando G, Raspa G, Piazza B, Babuin L, Chen HH, Martin FL, McKie PM, Heublein DM, Burnett JC Jr, Malatino LS.

Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1529-35. Epub 2006 Apr 28.

18.

Left ventricular systolic function monitoring in asymptomatic dialysis patients: a prospective cohort study.

Zoccali C, Benedetto FA, Tripepi G, Mallamaci F, Rapisarda F, Seminara G, Bonanno G, Malatino LS.

J Am Soc Nephrol. 2006 May;17(5):1460-5. Epub 2006 Apr 5.

19.

The E-selectin gene polymorphism and carotid atherosclerosis in end-stage renal disease.

Testa A, Benedetto FA, Spoto B, Pisano A, Tripepi G, Mallamaci F, Malatino LS, Zoccali C.

Nephrol Dial Transplant. 2006 Jul;21(7):1921-6. Epub 2006 Mar 22.

PMID:
16554320
20.

Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD.

Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C.

Kidney Int. 2005 Jun;67(6):2330-7.

21.

Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression.

Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS.

Kidney Int. 2004 Apr;65(4):1492-8.

22.

Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients.

Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS.

J Am Soc Nephrol. 2004 Apr;15(4):1029-37.

23.

Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.

Cataliotti A, Boerrigter G, Costello-Boerrigter LC, Schirger JA, Tsuruda T, Heublein DM, Chen HH, Malatino LS, Burnett JC Jr.

Circulation. 2004 Apr 6;109(13):1680-5. Epub 2004 Mar 15.

PMID:
15023890
24.

Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients.

Panuccio V, Tripepi R, Tripepi G, Mallamaci F, Benedetto FA, Cataliotti A, Bellanuova I, Giacone G, Malatino LS, Zoccali C.

Am J Kidney Dis. 2004 Mar;43(3):479-84.

PMID:
14981606
25.

Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease.

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Iellamo D, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS.

J Am Soc Nephrol. 2003 Oct;14(10):2611-7.

26.

Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure.

Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Stancanelli B, Nicocia G, Buemi M.

J Intern Med. 2003 Aug;254(2):132-9.

27.

Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD).

Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Bonanno G, Seminara G, Fatuzzo P, Rapisarda F, Malatino LS.

Kidney Int. 2003 Aug;64(2):579-84.

28.

Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease.

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS.

J Hypertens. 2003 Jul;21(7):1355-62.

PMID:
12817184
29.

Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure.

Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Nicocia G, Buemi M.

Eur J Clin Invest. 2003 Jul;33(7):561-6.

PMID:
12814392
30.

Hepatocyte growth factor and left ventricular geometry in end-stage renal disease.

Malatino LS, Cataliotti A, Benedetto FA, Stancanelli B, Bellanuova I, Belluardo P, Bonaiuto L, Tripepi G, Mallamaci F, Castellino P, Zoccali C.

Hypertension. 2003 Jan;41(1):88-92.

PMID:
12511535
31.

Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients.

Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS; Cardiovascular Risk Extended Evaluation in Dialysis Investigators.

Kidney Int. 2002 Nov;62(5):1884-90.

32.

CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome.

Cataliotti A, Giordano M, De Pascale E, Giordano G, Castellino P, Jougasaki M, Costello LC, Boerrigter G, Tsuruda T, Belluardo P, Lee SC, Huntley B, Sandberg S, Malatino LS, Burnett JC Jr.

Am J Physiol Renal Physiol. 2002 Sep;283(3):F464-72.

33.

Exaggerated endothelin release in response to acute mental stress in patients with intermittent claudication.

Mangiafico RA, Malatino LS, Attinà T, Messina R, Fiore CE.

Angiology. 2002 Jul-Aug;53(4):383-90.

PMID:
12143942
34.

Norepinephrine and concentric hypertrophy in patients with end-stage renal disease.

Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS; CREED investigators.

Hypertension. 2002 Jul;40(1):41-6.

PMID:
12105136
35.

Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients.

Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS.

Am J Kidney Dis. 2002 Jul;40(1):68-75.

PMID:
12087563
36.

Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients.

Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Böger R; CREED Investigators.

Kidney Int. 2002 Jul;62(1):339-45.

37.

Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease.

Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS.

Circulation. 2002 Mar 19;105(11):1354-9. Erratum in: Circulation 2002 May 7;105(18):2230. Cateliotti A [corrected to Cataliotti A].

PMID:
11901048
38.

Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients.

Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A; CREED Investigators.

Kidney Int. 2002 Feb;61(2):609-14.

39.

Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure.

Cataliotti A, Boerrigter G, Chen HH, Jougasaki M, Costello LC, Tsuruda T, Lee SC, Malatino LS, Burnett JC Jr.

Circulation. 2002 Feb 5;105(5):639-44.

PMID:
11827932
40.

Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease.

Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Böger R; CREED Investigators.

J Am Soc Nephrol. 2002 Feb;13(2):490-6.

41.

Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y.

J Am Soc Nephrol. 2002 Jan;13(1):134-41.

42.

Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis.

Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS; CREED Investigators.

J Am Soc Nephrol. 2001 Dec;12(12):2768-74.

43.

Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling.

Cataliotti A, Malatino LS, Jougasaki M, Zoccali C, Castellino P, Giacone G, Bellanuova I, Tripepi R, Seminara G, Parlongo S, Stancanelli B, Bonanno G, Fatuzzo P, Rapisarda F, Belluardo P, Signorelli SS, Heublein DM, Lainchbury JG, Leskinen HK, Bailey KR, Redfield MM, Burnett JC Jr.

Mayo Clin Proc. 2001 Nov;76(11):1111-9.

PMID:
11702899
44.

Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients.

Enia G, Mallamaci F, Benedetto FA, Panuccio V, Parlongo S, Cutrupi S, Giacone G, Cottini E, Tripepi G, Malatino LS, Zoccali C.

Nephrol Dial Transplant. 2001 Jul;16(7):1459-64.

PMID:
11427641
45.

Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients.

Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS; Creed Investigators.

J Am Soc Nephrol. 2001 Jul;12(7):1508-15.

46.

Diagnostic potential of cardiac natriuretic peptides in dialysis patients.

Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Stancanelli B, Malatino LS; CREED Investigstors. The Cardiovascular Risk Extended Evaluation.

Kidney Int. 2001 Apr;59(4):1559-66.

47.

Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease.

Malatino LS, Mallamaci F, Benedetto FA, Bellanuova I, Cataliotti A, Tripepi G, Zoccali C.

Am J Kidney Dis. 2000 Nov;36(5):945-52.

PMID:
11054350
48.

Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients.

Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Focà A, Paroni R, Malatino LS.

J Hypertens. 2000 Sep;18(9):1207-13.

PMID:
10994751
49.

Renal endothelin-1 is linked to changes in urinary salt and volume in essential hypertension. Salt Sensitivity Group of the Italian Society of Hypertension.

Malatino LS, Bellanuova I, Cataliotti A, Cuzzola F, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Mangiafico RA, Ferri C, Galletti F, Glorioso N, Strazzullo P, Zoccali C.

J Nephrol. 2000 May-Jun;13(3):178-84.

PMID:
10928293
50.

Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication.

Mangiafico RA, Messina R, Attinà T, Dell'Arte S, Giuliano L, Malatino LS.

Angiology. 2000 Jun;51(6):441-9.

PMID:
10870853

Supplemental Content

Loading ...
Support Center